Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia (ITP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified January 2013 by Mohsen Saleh Elalfy, Ain Shams University.
Recruitment status was: Not yet recruiting

Sponsor:

Information provided by (Responsible Party):

Mohsen Saleh Elalfy, Ain Shams University

ClinicalTrials.gov Identifier:

NCT01763658

First received: January 6, 2013

Last updated: January 8, 2013

Last verified: January 2013

History of Changes

Purpose

Oxidative stress occurs as a result of increased activity of free radical-producing enzymes, decreased activity of free radical-removing enzymes, and insufficient levels of antioxidants. The most sensitive molecules to oxidation are lipids. Loss of cell membrane elasticity, increased cell fragility, and a shortened cellular life span results from oxidation of cell membrane lipids.

Condition	Intervention	Phase
Immune Thrombocytopenia	Drug: Antox tablets(Mepaco) Other: drug therapy for ITP	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: immune thrombocytopenia thrombotic thrombocytopenic purpura

MedlinePlus related topics: Antioxidants

Genetic and Rare Diseases Information Center resources: Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenia

U.S. FDA Resources

Further study details as provided by Mohsen Saleh Elalfy, Ain Shams University:

Primary Outcome Measures:

oxidant status in ITP [ Time Frame: 6 month ]
oxidant and antioxidant systems initially in patients with acute and chronic immune thrombocytopenia (ITP)

Secondary Outcome Measures:

antioxidant therapy [ Time Frame: 6 months ]
antioxidant therapy on bleeding score, platelet count and antioxidant status


Estimated Enrollment:	100
Study Start Date:	March 2013
Estimated Study Completion Date:	September 2013
Estimated Primary Completion Date:	September 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Antioxidant, drug therapy for ITP interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.	Drug: Antox tablets(Mepaco) effect of antioxidant on disease outcome Other Name: antioxidant drug Other: drug therapy for ITP drugs will be selected according to ASH,2011 guidelines Other Names: dexamethasone prednisolone solumedrol Anti-D intravenous immunoglobulin romioplastin
Active Comparator: drug therapy for ITP drug therapy for ITP according to ASH, 2011 guidelines.	Other: drug therapy for ITP drugs will be selected according to ASH,2011 guidelines Other Names: dexamethasone prednisolone solumedrol Anti-D intravenous immunoglobulin romioplastin

Detailed Description:

Free oxygen radicals may have an effect on the structural and functional damage of platelets and plays a role in pathogenesis of thrombocytopenia in both, acute and chronic ITP.

Selenium is an essential mineral found in small amounts in the body. It works as an antioxidant, especially when combined with other antioxidants as vitamin E , A and C. Antioxidants neutralize free radicals and may reduce or even help prevent some of the damage they cause.

aim of this study is to assess oxidant and antioxidant systems initially in patients with acute and chronic immune thrombocytopenia (ITP) and 6 months later.Another aim of the study is to evaluate effect of antioxidant therapy on bleeding score, platelet count and antioxidant status during 6 months follow-up.

Eligibility


Ages Eligible for Study:	1 Year to 18 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. All patients less than 18 years with primary ITP; at initial presentation with platelet count less than 40 x 109/L attended Ain Shams Hematology clinic Children hospital from January 2013 and followed-up for 6 months.

2. For acute ITP, patients will be newly diagnosed (about one month within the diagnosis).

3. For chronic (12-24 months) and persistent (3-12 months) ITP patients.

Exclusion Criteria:

Patients' platelet count more than 40 x 109/L.; or above 18 years
Patients with secondary cause for thrombocytopenia.
Patients with any there associated chronic illness affecting oxidant status

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01763658

Contacts


Contact: yasmine I Elhenawy, lecturer	0104084038	dr_yasmi@yahoo.com

Locations


Egypt
hematology clinic ,pediatrics hospital, Ain Shams University hospital Cairo, Egypt	Not yet recruiting
Cairo, Egypt
Contact: Mohsen Saleh Elalfy, professor
Principal Investigator: Mohsen Saleh Elalfy, professor

Sponsors and Collaborators

Ain Shams University

Investigators


Principal Investigator:	Mohsen S Elalfy, professor	Ain Shams University

More Information


Responsible Party:	Mohsen Saleh Elalfy, professor of pediatrics, Ain Shams University
ClinicalTrials.gov Identifier:	NCT01763658 History of Changes
Other Study ID Numbers:	Antioxident in ITP
Study First Received:	January 6, 2013
Last Updated:	January 8, 2013

Keywords provided by Mohsen Saleh Elalfy, Ain Shams University:


ITP, antioxidant therapy, oxidant status

Additional relevant MeSH terms:


Thrombocytopenia Purpura, Thrombocytopenic, Idiopathic Blood Platelet Disorders Hematologic Diseases Purpura, Thrombocytopenic Purpura Blood Coagulation Disorders Thrombotic Microangiopathies Hemorrhagic Disorders Autoimmune Diseases Immune System Diseases Hemorrhage	Pathologic Processes Skin Manifestations Signs and Symptoms Immunoglobulins Immunoglobulins, Intravenous gamma-Globulins Rho(D) Immune Globulin Antioxidants Immunologic Factors Physiological Effects of Drugs Molecular Mechanisms of Pharmacological Action Protective Agents

ClinicalTrials.gov processed this record on July 24, 2017

To Top